Only 2 weeks after its official launch, Vella Bioscience the company behind Vella Women’s Pleasure Serum, a clinically demonstrated pre-play topical serum that promotes increased arousal and lubrication, and more frequent, intense, and satisfying orgasms, has closed a $7 million seed II funding round, anchored by Aaron Fleck & Associates.
The oversubscribed funding round puts Vella Bioscience at over $50 million post-money valuation, positioning the company to move forward on its mission in putting science in service of every woman’s sexual empowerment.
“This is a critical milestone that will drive Vella Bioscience’s future growth and we’re grateful for the overwhelming support from a diverse network of investors,” said Chief Executive Officer Nial DeMena. “We exceeded our initial goal by more than $2 million.”
Co-founded by Dr. Harin Padma-Nathan, the lead Principal Investigator for Viagra and Cialis, Vella’s proprietary nano-encapsulated CBD technology delivers CBD beyond the skin to relax vaginal and clitoral smooth muscle to encourage arousal and orgasm. “Vella is arriving on the market at a pivotal moment when major changes in the cultural acceptance of female sexual pleasure are happening,” said Chief Operating Officer Carolyn Wheeler. “We are leading the charge of exemplifying that women’s sexual wellness is an integral part of women’s health, happiness, and right to pleasure.”
With this new funding, Vella Bioscience plans to advance its product portfolio of science-driven innovations, further strengthening the promise of sexual empowerment for all women.
